<DOC>
	<DOC>NCT01254136</DOC>
	<brief_summary>This Phase I/II study is designed to assess the safety and therapeutic effect of INCB007839 in combination with trastuzumab and vinorelbine in patients with metastatic HER2+ breast cancer.</brief_summary>
	<brief_title>Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Subject with diagnosis of metastatic (or locally recurrentinoperable) breast cancer Subject with histological HER2+ status as determined by FISH with a gene amplification score of â‰¥ 2.2 Subject with availability of archival biopsy tissue from primary tumor or metastatic lesions Subject with presence of measurable disease based on RECIST 1.1 Subject who has received no more than three prior HER2directed therapeutic regimens for advanced breast cancer Subject with Left ventricular ejection fraction (LVEF) below institutional normal range Subject with metastasis to the central nervous system UNLESS asymptomatic and clinically stable Subject with current active malignancy other than breast cancer Subject with prior history of other malignancy except for cancers from which the patient is currently disease free Subject with significant renal or hepatic dysfunction Subject with history of venous or arterial thrombosis or risk factor for thrombosis other than history of malignancy Subject with insufficient bone marrow function Subject with contraindication to vinorelbine, trastuzumab, aspirin and/or warfarin therapy. Subject with current active bacterial, Hepatitis B or C, and/or HIV infections</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>